[Vigabatrin in the treatment of epilepsy in patients with West syndrome and tuberous sclerosis].
OBJECTIVE
To report the efficacy of vigabatrin in seizures control, as well as the electroencephalographic abnormalities in children with tuberous sclerosis and West syndrome.


METHODS
Retrospective study, with clinical, neuroimaging, and electroencephalographic data.


RESULTS
Seven patients were followed, and the median time of follow-up was 10 years. Four of them were females and all were white. The mean age of seizures onset was 3.4 months. All patients used antiepileptic drugs associations, at least 2 drugs each therapeutic scheme, each one of the patients have used at least two different schemes. Vigabatrin as monotherapy or adjuvant was started in a mean age of seven years or 4 years after the onset of symptoms. Five from seven patients on vigabatrin became seizure free.


CONCLUSIONS
Vigabatrin was efficient in seizures control, leading to a better prognosis.
Rotta
Newra Tellechea
NT
Unidade de Neurologia Pediátrica, Hospital de Clínicas de Porto Alegre, Porto Alegre RS, Brasil.
da Silva
Alexandre Rodrigues
AR
Ohlweiler
Lygia
L
Riesgo
Rudimar
R
D017668:Age of Onset; D000927:Anticonvulsants / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004569:Electroencephalography / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D011379:Prognosis; D012189:Retrospective Studies; D013036:Spasms, Infantile / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome; D014402:Tuberous Sclerosis / Q000150:complications / Q000188:drug therapy*; D020888:Vigabatrin / Q000627:therapeutic use*
D000927:Anticonvulsants; D020888:Vigabatrin